kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human Flt3-Ligand Protein, 20µg  

Recombinant Human Flt3-Ligand Protein, 20µg

Human Flt-3 Ligand Protein, His Tag

Recombinant human Flt-3 Ligand / FLT3LG (rhFLT3LG) Met1-Pro185 (Accession # AAI26294 ) was produced in human HEK293 cells.

More details


Availability: within 7 days

216,00 €


Human Flt-3 Ligand, His Tag (FLL-H5223) is expressed from human 293 cells (HEK293). It contains AA Thr 27 - Pro 185 (Accession # P49771-1).
Predicted N-terminus: Thr 27

Molecular Characterization
rhFLT3LG, fused with 6×his tag at the C-terminal and has a calculated MW of 18.9 kDa expressed. The predicted N-terminal is Thr27. Protein migrates as 18-30 kDa in reduced SDS-PAGE resulting from glycosylation.

Less than 1.0 EU per 1 μg of the rhFLT3LG by the LAL method.

>90% as determined by SDS-PAGE. 

Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Immobilized Human Flt-3, Fc Tag (Cat. No. FL3-H5258) at 5 μg/mL (100 μL/well) can bind Human Flt-3 Ligand, His Tag (Cat. No. FLL-H5223) with a linear range of 0.1-0.6 ng/mL (QC tested).

FMS-like tyrosine kinase 3 ligand (Flt-3 Ligand), also known as FL, Flt3L and FLT3LG, is an α-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages (1). FLT3LG is expressed as a noncovalentlylinked dimer by T cells and bone marrow and thymic fibroblasts (1, 2). Each 36 kDa chain carries approximately 12 kDa of N- and O- linked carbohydrates (2). FLT3LG is structurally homologous to stem cell factor (SCF) and colony stimulating facor 1 (CSF-1). FLT3LG acts as a growth factor that increases the number of immune cells by activating the hematopoietic progenitors. It also induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3LG induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation (2-3). FLT3LG cooperates with IL2, IL6, IL7, and IL15 to induce NK cell development and with IL3, IL7 and IL11 to induce terminal B cell maturation (1, 4). Animal studies also show FLT3LG to reduce the severity of experimentally induced allergic inflammation. FLT3LG is crucial for steady-state pDC and cDC development.[5] A lack of FLT3L results in low levels of DCs.

(1) Wodnar-Filipowicz A., 2003, News Physiol Sci., 18:247-51.
(2) McClanahan T., et al., 1996, Blood, 88(9):3371-82.
(3) Diener K.R. et al., 2008, Exp Hematol., 36(1):51-60.
(4) Farag SS, Caligiuri MA, 2006, Blood Rev. 20(3):123-37.
(5) Shortman, Ken, et al., 2006, Nature Reviews Immunology 7 (1): 19–30.